Moderna, Inc. (FRA:0QF)

Germany flag Germany · Delayed Price · Currency is EUR
36.73
-2.71 (-6.88%)
At close: Jan 30, 2026
-7.03%
Market Cap14.49B +11.5%
Revenue (ttm)1.90B -56.1%
Net Income-2.66B
EPS-6.86
Shares Outn/a
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume672
Average Volume2,955
Open37.50
Previous Close39.44
Day's Range36.73 - 38.09
52-Week Range19.26 - 46.96
Betan/a
RSI55.92
Earnings DateFeb 13, 2026

About Moderna

Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company’s respiratory vaccines include spikevax, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, su... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2010
Employees 5,800
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol 0QF
Full Company Profile

Financial Performance

In 2024, Moderna's revenue was $3.24 billion, a decrease of -52.75% compared to the previous year's $6.85 billion. Losses were -$3.56 billion, -24.46% less than in 2023.

Financial numbers in USD Financial Statements

News

PROFFITT & GOODSON INC Sells 150 Shares of Moderna Inc (MRNA)

PROFFITT & GOODSON INC Sells 150 Shares of Moderna Inc (MRNA)

20 hours ago - GuruFocus

Bayforest Capital Ltd Buys 6,812 Shares of Moderna Inc (MRNA)

Bayforest Capital Ltd Buys 6,812 Shares of Moderna Inc (MRNA)

20 hours ago - GuruFocus

Noteworthy Friday Option Activity: V, MRNA, WDC

Among the underlying components of the S&P 500 index, we saw noteworthy options trading volume today in Visa Inc (Symbol: V), where a total of 45,386 contracts have traded so far, representing approxi...

1 day ago - Nasdaq

Moderna (MRNA) Announces Leadership Changes Amid Strategic Shift

Moderna (MRNA) Announces Leadership Changes Amid Strategic Shift

1 day ago - GuruFocus

Moderna Vs. Novavax: 2 Pandemic Vaccine Pioneers - Which Offers Better Value Today?

Moderna, Inc. and Novavax, Inc. have transitioned from pandemic-era highs to focusing on cost reduction, pipeline development, and a path to breakeven by 2028. NVAX leverages partnerships with Sanofi ...

1 day ago - Seeking Alpha

Moderna CMO Jacqueline Miller to step down

Moderna's Chief Medical Officer Jacqueline Miller, who led the development of the company's mRNA-based COVID-19 vaccine Spikevax, will step down effective March 2, the vaccine maker said on Friday.

1 day ago - Reuters

Moderna, Inc.: Dr. David Berman to Join Moderna as Chief Development Officer

CAMBRIDGE, MASSACHUSETTS / ACCESS Newswire / January 30, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that David Berman, M.D., Ph.D. has been appointed as the Company's Chief Development Offi...

1 day ago - Finanz Nachrichten

Dr. David Berman to Join Moderna as Chief Development Officer

CAMBRIDGE, MASSACHUSETTS / ACCESS Newswire / January 30, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that David Berman, M.D., Ph.D. has been appointed as the Company's Chief Development Officer...

1 day ago - Accesswire

Dr. David Berman to Join Moderna as Chief Development Officer

CAMBRIDGE, MASSACHUSETTS / ACCESS Newswire / January 30, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that David Berman, M.D., Ph.D. has been appointed as the Company's Chief Development Officer...

1 day ago - Wallstreet:Online

Moderna (MRNA) Partners with Recordati for mRNA-3927 Development and Marketing

Moderna (MRNA) Partners with Recordati for mRNA-3927 Development and Marketing

2 days ago - GuruFocus

RECORDATI ANNOUNCES STRATEGIC COLLABORATION WITH MODERNA TO DEVELOP AND COMMERCIALIZE WORLDWIDE mRNA 3927 FOR THE TREATMENT OF PROPIONIC ACIDEMIA

mRNA-3927 is a strong strategic fit with Recordati's rare Metabolic portfolio Collaboration combines Moderna's expertise in mRNA technology for rare metabolic disorders with Recordati's established gl...

2 days ago - GlobeNewsWire

Moderna, Inc.: Moderna Announces Strategic Collaboration with Recordati to Globally Commercialize Investigational Propionic Acidemia Therapeutic

Moderna will continue to lead clinical development and manufacturing for mRNA-3927Moderna to receive up to $160 million in upfront and near-term development and regulatory milestones, in addition t...

2 days ago - Finanz Nachrichten

Moderna Announces Strategic Collaboration with Recordati to Globally Commercialize Investigational Propionic Acidemia Therapeutic (mRNA-3927)

Moderna will continue to lead clinical development and manufacturing for mRNA-3927 Moderna to receive up to $160 million in upfront and near-term development and regulatory milestones, in addition to ...

2 days ago - Accesswire

Moderna Announces Strategic Collaboration with Recordati to Globally Commercialize Investigational Propionic Acidemia Therapeutic (mRNA-3927)

Moderna will continue to lead clinical development and manufacturing for mRNA-3927Moderna to receive up to $160 million in upfront and near-term development and regulatory milestones, in addition to c...

2 days ago - Wallstreet:Online

This Stock Is Already Up 58% This Year. Is It a Buy?

One of Moderna's leading drug candidates is proving highly effective in clinical trials. It could help expand Moderna's lineup and boost its financial results.

3 days ago - The Motley Fool

Moderna (MRNA) Leads Healthcare Stocks with Impressive Gains

Moderna (MRNA) Leads Healthcare Stocks with Impressive Gains

3 days ago - GuruFocus

Convergence Long/Short Equity ETF Buys 12,528 Shares of Moderna Inc (MRNA)

Convergence Long/Short Equity ETF Buys 12,528 Shares of Moderna Inc (MRNA)

3 days ago - GuruFocus

Victory Growth and Tax Strategy Fund Buys 3,438 Shares of Moderna Inc (MRNA)

Victory Growth and Tax Strategy Fund Buys 3,438 Shares of Moderna Inc (MRNA)

3 days ago - GuruFocus

Moderna, Inc (MRNA) Q2 2022 Earnings Call Transcript

Moderna, Inc (NASDAQ: MRNA) Q2 2022 Earnings Call dated Aug. 03, 2022 Corporate Participants: Lavina Talukdar — Senior Vice President and Head of Investor Relations Stephane Bancel — Chief Executive O...

4 days ago - AlphaStreet

Moderna (MRNA) Stock Pulls Back After Recent Strength

Moderna Inc (NASDAQ: MRNA) shares are down on Monday, pulling back after recent updates highlighting its latest cancer trial results. Here’s what investors need to know . Moderna stock is trending lo...

5 days ago - Benzinga

Behind the Scenes of Moderna's Latest Options Trends

Deep-pocketed investors have adopted a bearish approach towards Moderna (NASDAQ: MRNA), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled...

5 days ago - Benzinga

Moderna, Inc.: Moderna to Report Fourth Quarter 2025 Financial Results on Friday, February 13, 2026

CAMBRIDGE, MA / ACCESS Newswire / January 26, 2026 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Friday, February 13, 2026 t...

5 days ago - Finanz Nachrichten

Moderna to Report Fourth Quarter 2025 Financial Results on Friday, February 13, 2026

CAMBRIDGE, MA / ACCESS Newswire / January 26, 2026 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Friday, February 13, 2026 to r...

5 days ago - Wallstreet:Online